```
     FILE 'USPATFULL, CAPLUS' ENTERED AT 17:17:41 ON 17 JUL [illegible]
L1          [illegible] S NANOPARTICLE
L2           7036 S  METAL  W? SOAP?
L3         484978 S    FATTY OR CAPRYLIC OR CAPRIC OR HEXADECANOIC OR PALMITIC OR
L4        [illegible] S    ALKALI OR  ALKALINE  W  EARTH     W  METAL   [illegible]
L5         [illegible]45 S L3  [illegible]  L4  [illegible]  SALT
L6          [illegible]84 S  SODIUM OR MAGNESIUM OR POTASSIUM OR CALCIUM OR ALUMINUM OR Z
L7        [illegible] S ALUMINUM OR ZINC
L8           [illegible] S L3  [illegible]  L7  [illegible] SALT
L9          41684 S L5 OR L8
L10          1743 S  SODIUM OR MAGNESIUM OR POTASSIUM OR CALCIUM OR ALUMINUM OR Z
L11        115673 S L6 OR L9 OR L10
L12       [illegible] S COSMETIC? OR DERMATOLOG? OR PHARMACEUTICAL? OR MAKEUP OR TABL
L13           501 S L1 AND L11 AND L12
L14            56 S L1  [illegible]  L11
L15            34 S L13 AND L14
L16            13 S L15 AND PY<1999
```

Searches for User lwells (Count 5774)

Queries 5725 through 5774.

S #
Updt
Database
Query
Time
Comment

S5774
U
USPT,PGPB,JPAB,EPAB,DWPI
9911235.pn.
2003-07-30 07:25:50

S5773
U
USPT,PGPB,JPAB,EPAB,DWPI
metal soap same (nm or nanometer)
2003-07-29 16:08:09

S5772
U
USPT,PGPB,JPAB,EPAB,DWPI
metal soap near (nm or nanometer)
2003-07-29 16:07:45

S5771
U
USPT,PGPB,JPAB,EPAB,DWPI
((magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate)same (nm or nanometer)) and ((424/401)!.CCLS.)

2003-07-29 15:55:50
S5770
U
USPT,PGPB,JPAB,EPAB,DWPI
((magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate)near particle) and ((magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate)same (nm or nanometer))
2003-07-29 15:04:57
S5769
U
USPT,PGPB,JPAB,EPAB,DWPI
(magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate) near particle
2003-07-29 15:04:48
S5768
U
USPT,PGPB,JPAB,EPAB,DWPI
(magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate) near (nm or nanometer)
2003-07-29 15:04:35
S5767
U
USPT,PGPB,JPAB,EPAB,DWPI
(((magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate)same (nm or nanometer))same particle) and (424/401.ccls. or cosmetic)
2003-07-29 15:04:13
S5766
U
USPT,PGPB,JPAB,EPAB,DWPI
((magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or calcium stearate)same (nm or nanometer)) same particle
2003-07-29 15:04:01

S5765
U
USPT,PGPB,JPAB,EPAB,DWPI
(magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or
calcium stearate) same (nm or nanometer)
2003-07-29 15:03:47
S5764
U
USPT,PGPB,JPAB,EPAB,DWPI
magnesium stearate or aluminum stearate or zinc stearate or zinc hydroxystearate or calcium ricinoleate or
calcium stearate
2003-07-29 15:03:19
S5763
U
USPT,PGPB,JPAB,EPAB,DWPI
((metal soap)same particle) same (nm or nanometer)
2003-07-29 14:58:53
S5762
U
USPT,PGPB,JPAB,EPAB,DWPI
(metal soap) same particle
2003-07-29 14:57:49

L? ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1996:[illegible] CAPLUS
DN 125:[illegible]
TI Surface modified nanoparticles and method of making and using them
IN Levy, Robert J.; Labhasetwar, Vinod; Song, Cunxian X.
PA USA
SO PCT Int. Appl., [illegible] pp.
CODEN: PIXXD2
DT Patent
LA English
IC A61K009-51
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9620698	A2	19960711	WO 1996-US476	19960104
	WO 9620698	A3	19980122		
	W: AL, AM, AT, AU, CA, CH, CN, CZ, DE, DK, GB, HU, IS, JP, KE, LU, VN, MN, NO, US				
	RW: KE, LS, SD, AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, PT, SE, NL, MR, NE, SN				
	CA 2207961	AA	19960711	CA 1996-2207961	19960104
	AU 9647556	A1	19960724	AU 1996-47556	19960104
	EP 805678	A1	19971112	EP 1996-903476	19960104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	JP 10511957	T2	19981117	JP 1996-521279	19960104
PRAI	US 1995-369541		19950105		
	US 1995-389893		19950216		
	WO 1996-US476		19960104		

AB Biodegradable controlled-release nanoparticles as sustained release bioactive agent delivery vehicles include surface modifying agents to target binding of the nanoparticles to tissues or cells of living systems, to enhance nanoparticle sustained release properties, and to protect nanoparticle-incorporated bioactive agents. Unique methods of making small (10 nm to 15 nm, and preferably 20 nm to 35 nm) nanoparticles having a narrow size distribution which can be surface-modified after the nanoparticles are formed is described. Techniques for modifying the surface include a lyophilization technique to produce a phys. adsorbed coating and epoxy-derivatization to functionalize the surface of the nanoparticles to covalently bind mols. of interest. The nanoparticles may also comprise hydroxy-terminated or epoxide-terminated and/or activated multiblock copolymers, having hydrophobic segments which may be polycaprolactone and hydrophilic segments. The nanoparticles are useful for local intravascular administration of smooth muscle inhibitors and antithrombogenic agents as part of interventional cardiac or vascular catheterization such as a balloon angioplasty procedure; direct application to tissues and/or cells for gene therapy, such as the delivery of osteotropic genes or gene segments into bone progenitor cells; or oral administration in an enteric capsule for delivery of protein/peptide based vaccines.
ST polymer controlled release nanoparticle drug delivery; gene therapy vaccine controlled release nanoparticle
IT Animal growth regulators
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Fibrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glue, suspending medium; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Cardiovascular agents
(inhibitors and stimulators; surface-modified polymer

controlled-release nanoparticles for sustained drug delivery)
IT Animal tissue culture
(media; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Polymerization catalysts
(photoinitiation; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Buffer substances and systems
(physiol., suspending medium; surface modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Alkylating agents, biological
Antibiotics
Anticoagulants and Antithrombotics
Emulsifying agents
Encapsulation
Freeze drying
Immunosuppressants
Inflammation inhibitors
Neoplasm inhibitors
Sound and Ultrasound
Surfactants
Thrombolytics
Vaccines
(surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Agglutinins and Lectins
Antibodies
Beeswax
Biopolymers
Caseins, biological studies
Fatty acids, biological studies
Ferritins
Fibrinogens
Glycerides, biological studies
Hemoglobins
Lipids, biological studies
Myoglobins
Phosphatidylethanolamines
Phospholipids, biological studies
Polysaccharides, biological studies
Silicates, biological studies
Waxes and Waxy substances
Wool wax
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Albumins, biological studies
Alkaloids, biological studies
Antigens
Deoxyribonucleic acids
Enzymes
Gelatins, biological studies
Gene, animal
Glycoproteins, biological studies
Hormones
Nucleic acids
Osteocalcins
Phosphazene polymers
Phosphoproteins
Polyanhydrides
Polyesters, biological studies

Polyethers, biological studies
Quaternary ammonium compounds, biological studies
Ribonucleic acids
Toxins
Urethane polymers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Polymers, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface-modifying agents; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Blood serum
Physiological saline solutions
(suspending medium; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Peptides, biological studies
Proteins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccines based on; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Sialoglycoproteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BSP II (bone sialoglycoprotein II), surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Dental materials and appliances
(adhesives, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Quaternary ammonium compounds
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Artery
(angioplasty, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Surfactants
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anionic, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-onco-, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(blood platelet-derived growth factors, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Medical goods
(bone cements, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone morphogenetic proteins, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Ion channel blockers
(calcium, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Surfactants
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(cationic, surface-modified polymer controlled release nanoparticles for sustained drug delivery)

IT Quaternary ammonium compounds, uses
RL: CAT (Catalyst use); USES (Uses)
(complexes, surface-modified polymer controlled release nanoparticles for sustained drug delivery)

IT Alcohols, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Fats and Glycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Therapeutics
(geno-, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Gels
(hydro-, suspending medium; surface-modified polymer controlled release nanoparticles for sustained drug delivery)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 1.alpha., surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 1.beta., surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 6, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Trace elements, uses
RL: CAT (Catalyst use); USES (Uses)
(metals, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Antibodies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Pharmaceutical dosage forms
(nanoparticles, controlled-release, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Surfactants
(nonionic, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Nucleotides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligo-, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Polymers
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligomers, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Gene, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(onco-, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Polyethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho ester group-contg., surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Glycoproteins, uses
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osteonectins, surface-modified polymer controlled release nanoparticles for sustained drug delivery)
IT Glycophosphoproteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osteopontins, surface-modified polymer controlled release nanoparticles for sustained drug delivery)
IT Bone marrow
(osteoprogenitor cell, surface modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Polyamides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly(amino acids), surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Fatty acids, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium salts, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Collagens, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pro-, suspending medium; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Sterilization and Disinfection
(radiochem., surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Heart, disease
(restenosis, prevention of; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT **Soaps**
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rosin, surface-modified polymer controlled-release **nanoparticles** for sustained drug delivery)
IT Fatty acids, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium salts, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Oils
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonated, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Amines, uses
RL: CAT (Catalyst use); USES (Uses)
(tertiary, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Toxoids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetanus, vaccines based on; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Animal growth regulators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transforming growth factors, surface-modified polymer controlled-release nanoparticles for sustained drug delivery)
IT Lymphokines and Cytokines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor necrosis factor-.alpha., surface-modified polymer controlled release nanoparticles for sustained drug delivery)

IT Collagens, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type I, surface modified polymer controlled release nanoparticles for sustained drug delivery)

IT Collagens, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type II, surface modified polymer controlled-release nanoparticles for sustained drug delivery)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin K-dependent, surface-modified polymer controlled release nanoparticles for sustained drug delivery)

IT 62229-50-9, Epidermal growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heparin-binding, -like compds.; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 9015-82-1, Angiotensin-converting enzyme 9026-43-1, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 180741-23-5DP, reaction products with heparin
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(repeating units; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 67-64-1, 2-Propanone, biological studies 67-66-3, Chloroform, biological studies 67-68-5, Dimethylsulfoxide, biological studies 68-12-2, Dimethylformamide, biological studies 75-09-2, Methylene chloride, biological studies 109-99-9, biological studies 123-91-1, Dioxane, biological studies 127-19-5, Dimethylacetamide 141-78-6, Ethyl acetate, biological studies 684-16-2, Hexafluoroacetone 920-66-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solvent; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 75-23-0 75-47-8, Iodoform 102-54-5, Ferrocene 113-00-8, Guanidine 288-32-4, Imidazole, uses 558-13-4, Carbon tetrabromide 7550-45-0, Titanium tetrachloride, uses 7637-07-2D, Boron trifluoride, adducts 13598-36-2D, Phosphonic acid, alkylidenebis- derivs. 13826-88-5, Zinc tetrafluoroborate 86665-14-7, Zirconocene chloride
RL: CAT (Catalyst use); USES (Uses)
(surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 50-70-4, D-Glucitol, biological studies 57-09-0, Cetyl trimethyl ammonium bromide 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 69-65-8, D-Mannitol 102-71-6, Triethanolamine, biological studies 112-02-7, Hexadecyl trimethyl ammonium chloride 151-21-3, Sodium dodecyl sulfate, biological studies 577-11-7, Sodium dioctyl sulfosuccinate 1069-55-2, Isobutyl cyanoacrylate 3282-73-3, Didodecyldimethyl ammonium bromide 7445-62-7 7727-43-7, Barium sulfate 8007-43-0, Sorbitan sesquioleate 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-89-5, Polyvinyl alcohol 9002-92-0, Polyoxyethylene lauryl ether 9003-39-8, Polyvinyl pyrrolidone 9003-53-6, Polystyrene 9004-32-4 9004-34-6, Cellulose, biological studies 9004-35-7, Cellulose acetate 9004-44-8, Cellulose phthalate 9004-64-2, Hydroxypropyl cellulose 9004-99-3 9005-49-6, Heparin, biological studies 9015-73-0 9050-04-8, CM-cellulose calcium 9050-31-1, Hydroxypropyl methyl cellulose phthalate 10103-46-5, Calcium phosphate 25322-68-3 106392-12-5, Poloxamer 110617-70-4, Poloxamine 128835-92-7, Lipofectin 180741-27-9

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface modified polymer controlled release nanoparticles for sustained drug delivery)

IT [illegible]
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(surface modified polymer controlled release nanoparticles for sustained drug delivery)

IT [illegible], Heparin, reaction products with epoxide end-capped polymer 180741-24-0P 180741-25-7P 180741-26-8P 180801-36-9P 180801-37-0P 180801-38-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(surface modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 50-02-2, Dexamethasone 50-52-9 60-00-4, EDTA, biological studies 60-10-6, Dithizone 77-86-1 77-92-9, biological studies 87-69-4, biological studies 92-84-2D, Phenothiazine, derivs. 102-71-6D, Triethanolamine, fatty acid esters 139-13-9 144-62-7, Ethanedioic acid, biological studies 1306-06-5, Hydroxyapatite 1338-39-2, Span 20 2462-63-7 9000-01-5, Acacia gum 9003-05-8, Polyacrylamide 9004-54-0, Dextran, biological studies 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9012-76-4, Chitosan 10102-43-9D, Nitric oxide, compds. 11128-99-7, Angiotensin II 14930-96-2, Cytochalasin B 61912-98-9, Insulin-like growth factor 81845-44-5, Ciprostene 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 114949-22-3, Activin 122647-31-8, Ibutilide 130736-65-1, U 86983
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surface-modified polymer controlled-release nanoparticles for sustained drug delivery)

IT 7732-18-5, Water, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suspending medium; surface-modified polymer controlled-release nanoparticles for sustained drug delivery)